Form 604 Corporations Act 2001 Section 671B

Notice of change of Interests of substantial holder

T- O Nove/Schame	Opthea Limi	tod
To Company Name/Scheme	Optilea Liili	ied
ACN/ARSN	006 340 567	
Details of substantial holder (1)		
Name		rs LP on its own behalf and on behalf of BVF Inc., Mark N, Lampert and Biotechnology Value Fund, L.P. and gy Value Fund II, L.P.
ACN/ARSN (if applicable)		
There was a change in the interest substantial holder on:	s of the	
		28/11/2018
The previous notice was given to the company on		15/11/2018
The previous notice was dated		15/11/2018

2. Previous and present voting power

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in when last required, and when now required, to give a substantial holding notice to the company or scheme, are as follows:

	Previous notice		Present notice	
Class of securities (4)	Person's votes	Voting power (5)	Person's votes	Voting power (5)
Fully Paid Ordinary Shares (note: this row relates only to BVF Partners LP, BVF Inc., and Mark N. Lampert, and includes the votes and voting power in the next two rows)	37,705,918	16,39%	37,705,918	15.12%
Fully Paid Ordinary Shares (note: this row relates only to Biotechnology Value Fund, L.P. in respect of its registered holdings)	18,817,324	8,18%	18,817,324	7.54%
Fully Paid Ordinary Shares (note: this row relates only to Biotechnology Value Fund II, L.P. in respect of its registered holdings)	13,582,134	5.90%	13,582,134	5.45%

3. Changes in relevant interests

Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

Date of change	Person whose relevant interest changed	Nature of change (6)	Consideration given in relation to change (7)	Class and number of securities affected	Person's votes affected
----------------	----------------------------------------------	-------------------------	-----------------------------------------------------	--------------------------------------------------	----------------------------

Dilution of interest following issuance of 13,569,351 shares by OPT on 28/11/2018 pursuant to the exercise of quoted options.

4. Present relevant Interests

Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows:

Holder of relevant interest	Registered holder of securities	entitled to be registered as holder (8)	Nature of relevant interest (6)	Class and number of securities	Person's votes	
-----------------------------	---------------------------------------	--------------------------------------------------	---------------------------------------	--------------------------------------	----------------	--

			<u> </u>		
BVF Partners, L.P.	HSBC Custody Nominees (Australia) Limited and BNP Paribas Nominees Pty Ltd	Value Fund, L.P, Biotechnology Value Fund II, L.P, Biotechnology Value Trading Fund OS, L.P., Investment 10 LLC, MSI BVF	Relevant interest arises under section 608(1)(b) of the Corporations Act 2001 (Cth) (Corporations Act) by virtue of BVF Partners, L.P. (i) acting as general partner of, and/or (ii) acting as investment manager of, respectively, the registered holders of the securities, whereby it holds the authority to cast votes in respect of the securities.	37,705,918 fully paid ordinary shares	37,705,918
BVF Inc. and Mark N. Lampert	HSBC Custody Nominees (Australia) Limited and BNP Paribas Nominees Pty Ltd	Biotechnology Value Fund, L.P, Biotechnology Value Fund II, L.P, Biotechnology Value Trading Fund OS, L.P., Investment 10 LLC, MSI BVF SPV, LLC, as per their relevant interests below.	Relevant interest arises under section 608(3)(b) of the Corporations Act as each of BVF Inc. and Mark N. Lampert controls BVF Partners, L.P.	37,705,918 fully paid ordinary shares	37,705,918
BVF Partners OS Ltd.	HSBC Custody Nominees (Australia) Limited	Biotechnology Value Trading Fund OS, L.P.	Relevant interest arises under section 608(1)(b) of the Corporations Act by virtue of BVF Partners OS, Ltd. acting as general partner of Biotechnology Value Trading Fund OS, L.P., a registered holder of securities, whereby it holds the authority to cast votes in respect to the securities.	3,230,046 fully paid ordinary shares	3,230,046
Biotechnology Value Trading Fund OS, L.P.	HSBC Custody Nominees (Australia) Limited	Biotechnology Value Trading Fund OS, L.P.	Relevant interest arises under section 608(1) of the Corporations Act as beneficial owner of the securities	3,230,046 fully paid ordinary shares	3,230,046
Biotechnology Value Fund, L.P.	HSBC Custody Nominees (Australia) Limited	Biotechnology Value Fund, L.P.	Relevant interest arises under section 608(1) of the Corporations Act as beneficial owner of the securities	18,817,324 fully paid ordinary shares	18,817,324
Biotechnology Value Fund II, L.P.	HSBC Custody Nominees (Australia) Limited	Biotechnology Value Fund II, L.P.	Relevant interest arises under section 608(1) of the Corporations Act as beneficial owner of the securities	13,582,134 fully paid ordinary shares	13,582,134
MSI BVF SPV, LLC	BNP Paribas Nominees Pty Ltd	MSI BVF SPV, LLC	Relevant interest arises under section 608(1) of the Corporations Act as beneficial owner of the securities	2,076,414 fully paid ordinary shares	2,076,414

5. Changes in association

The persons who have become associates (2) of, ceased to be associates of, or have changed the nature of their association (9) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

Name applicable	and)	ACN/ARSN	(if	Nature of association
Not applicable N			Not applicable	

6. Addresses

The addresses of persons named in this form are as follows:

|--|

BVF Partners LP Biotechnology Value Fund, L.P. Biotechnology Value Fund II, L.P. BVF Inc.	44 Montgomery, 40 th Floor San Francisco, California 94104 United States of America
BVF Partners OS, Ltd Biotechnology Value Trading Fund OS, L.P.	PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands
Investment 10 LLC	900 North Michigan Avenue, Suite 1100 Chicago, Illinois 60611 United States of America
MSI BVF SPV, LLC	c/o Magnitude Capital, L.L.C. 601 Lexington Avenue, 59 th Floor New York, NY 10022
Mark N. Lampert	c/o BVF Inc 44 Montgomery, 40 th Floor San Francisco, California 94104 United States of America

Signature

BVF Partners LP BY BVF Inc., its general partner, BY Mark N. Lampert, print name President

capacity

General Partner and Attorney-in-Fact for the Substantial Holders

sign here

My In

date

30/11/2018